Clinical Trial

A Pilot Study in Severe Patients With Takayasu Arteritis.

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 10, 2021 (before its estimated May 1, 2022 completion). Its status may not reflect the trial's current state.
Summary
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-03-06; most recent amendment 2023-06-07.
Status change: Recruiting → Completed 2023-06-07
Trial Details
NCT Number NCT04300686
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
Enrollment 40 participants
Start Date 2020-03-01
Primary Completion 2022-05-01 (estimated)
Study Completion 2023-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-08-10